The dose escalation is a modest, expected milestone for a Phase 1 trial and does not provide new efficacy data. The recent dilutive offering at a 26% discount overshadows this news for a pre-revenue company with a $36M market cap. Monitor for future safety/efficacy readouts and cash runway updates.
Price Chart
Executive Summary
Radiopharm Theranostics received a positive DSMC recommendation to advance its Phase 1 HEAT trial of 177Lu-RAD202 to Cohort 4 at 180mCi in HER2+ advanced solid tumors, following a prior diagnostic study showing proof-of-concept. The trial dose escalation is a routine Phase 1 step with no new efficacy or safety data disclosed, and the company remains pre-revenue with a dilutive capital raise completed 24 days prior.
Key Facts
- DSMC recommended advancing RAD202 Phase 1 HEAT trial to Cohort 4 at 180mCi dose level.
- Prior diagnostic study in 10 HER2-positive breast cancer patients showed clinical proof-of-concept with positive safety and biodistribution.
- Previous dose level of 130mCi was announced on April 8, 2026.
- The company completed a dilutive ~$4.05M registered direct offering at a ~26% discount on July 27, 2026, combined with an Australian Placement and Share Purchase Plan.
- Radiopharm is a clinical-stage, pre-revenue biopharmaceutical company.
Financial Impact
No financial figures disclosed in the filing. The company is pre-revenue with a recent dilutive capital raise of approximately $4.05M USD.
Risk Factors
- No new safety or efficacy data disclosed; Phase 1 dose escalation is standard and does not de-risk the asset.
- Recent dilutive capital raise at a steep discount signals urgent cash needs and significant shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-091896 |
| Document: ea0302833-6k_radiopharm.htm | 0001213900-26-091896 |
| Document: 0001213900-26-091896-index-headers.html | 0001213900-26-091896 |
| Document: 0001213900-26-091896-index.html | 0001213900-26-091896 |
| Document: 0001213900-26-091896.txt | 0001213900-26-091896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers